Background
==========

Long-term exercise training has been associated with weight loss, improvements in lipid profile and blood pressure, and cardiac remodeling \[[@B1]-[@B3]\]. Despite this, the cardiovascular response to high-intensity training in previously untrained individuals is not well characterized. Importantly, even with extreme marathon and half-marathon (HM) exercise training, individuals may experience varying levels of cardiovascular and physiological changes, and these differences may have a biological basis. For example, HM and marathon training have been associated with increases in oxidative stress and myocardial damage \[[@B4]-[@B9]\]. HM and marathon training also induces the release of troponin I and T, markers of myocardial injury; elevations in cardiac troponin T (cTnT) are reported in up to 39-56% of athletes immediately after performance \[[@B10]\]. Although the mechanism and implications are not well defined, these biomarkers usually return to normal within 24 to 48 hours, and the magnitude of biomarker peak is inversely related to the level of training prior to the event \[[@B10]\]. The purpose of our study was to assess time-related cardiovascular performance and function and corresponding gene expression changes in participants undergoing HM training. Our goal is to begin to identify a genomic basis for response to exercise by correlating specific changes in gene expression with the physiologic changes following HM training.

Methods
=======

Apparently healthy, untrained and sedentary males (n = 47), between 18 and 45 years of age, participated in the study. Candidates were required to have engaged in less than 2 hours of aerobic training per week prior to enrollment, have an average maximum oxygen consumption (VO~2~ max) less than 50 ml/kg/min, and not previously completed a HM. Twenty-four of the subjects, who were enrolled in a local HM Training Program, were recruited into the training group (TRAIN), and twenty-three male subjects of similar age were recruited into the control group (CON). The CON group did not participate in the training program or undergo any lifestyle modification over the 16 week duration of the study. All subjects volunteered for the study and signed informed consents. TRAIN subjects were compensated for meals, travel time, and training program fees. Exclusion criteria included smoking, known metabolic or cardiovascular conditions (diabetes or dyslipidemia), chronic inflammatory diseases, or chronic use of non-steroidal anti-inflammatory drugs. The protocol was approved by the University of Miami Institutional Review Board for human subjects research.

Initial screening and evaluation included a complete medical and training history, baseline VO~2~ max test, resting heart rate, blood pressure, height, weight, body composition assessment, serum biomarkers, and complete echocardiographic evaluation. Body composition was assessed through dual-energy X-ray absorptiometry scanning. Blood for the lipid panels and serum biomarkers was drawn via the antecubital vein using the LeukoLock Protection system and stored at −80°C for analyses with the post-training RNA samples. Lipid panels were done on fasted blood samples. TRAIN and CON subjects had heart rate, blood pressure, height, weight, and serum biomarkers repeated at 6, 11, and 16 weeks after the baseline evaluation. Echocardiograms, VO~2~ max, and body fat evaluation were recorded at baseline and 16 weeks after the baseline evaluation.

Of the 24 subjects enrolled in the TRAIN group, 5 subjects were unable to complete the training due to injury or time constraints and withdrew prior to the peak training data (week 16) collection. Three subjects were able to complete the peak training data collection, but were unable to complete the HM due to injury. Thus, a total of 19 subjects completed the program with peak training data collected. Of these 19 subjects, 16 subjects completed the 2007 Miami HM and had blood drawn within 30 minutes after the race (see Figure [1](#F1){ref-type="fig"}). Of the CON group, one individual was unable to continue the study as a result of scheduling difficulty, leaving a total of 22 controls that completed all data collection.
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Two-dimensional echocardiograms with pulsed-Doppler imaging were acquired on each subject using a commercial system (Philips HD11). Standard measurements were performed according to the American Society of Echocardiography guidelines \[[@B11]\]. Interventricular septal wall thickness, LV internal diameter, and LV posterior wall thickness were measured in systole and diastole in the parasternal long axis view. The LV end-diastolic volume, LV end-systolic volume, stroke volume, and ejection fraction were calculated via modified bi-planer calculation based on the apical 2 and 4 chamber view. LV mass was calculated using the area length method. With the pulsed-Doppler trans-mitral filling velocities (peak early \[E'\] and late \[atrial-A'\]), diastolic function was assessed and an E/A ratio was determined. One certified echocardiogram technician was responsible for acquiring all images for each participant. The measurements and calculations were independently confirmed by an experienced echocardiographer. Both were blinded to each subject's group status.

Blood was collected in EDTA and standard red top tubes (serum) and processed immediately. Tubes were immediately centrifuged, and the serum was separated and stored in a -80° freezer. Serum was analyzed for cTnT \[[@B12]\], CRP \[[@B12]\], and lipids (HDL, LDL, and TG) \[[@B12]\]. Blood for RNA extraction was collected at both baseline and peak training (week 16) using the Ambion LeukoLOCK system that captured and preserved the blood mononuclear cell layer.

Clinical and biomarker data were analyzed using SPSS for Windows 15.0 software (SPSS, Inc, Chicago, IL). Frequency and descriptive statistics were calculated to check all relevant characteristics of the data. Independent samples *t*-tests were used to compare baseline variable differences between the TRAIN and CON groups. Paired samples *t*-tests were used to compare changes from baseline to peak training or baseline to post-HM.

Microarray analysis was performed on blood collected from each subject at baseline and at 16 weeks. Total RNA was extracted and analyzed using the Affymetrix GeneChip Human Gene ST array, which has 28,869 unique genes (or transcripts) which are captured by \~26 probes per gene. Data were normalized using Robust Multi-Array (RMA) Normalization. Significance Analysis of Microarray (SAM) Software \[[@B13]\] was used to determine statistically significant genes that met predetermined False Discovery Rate (FDR) thresholds. SAM uses non-parametric statistics and gene specific *t*-tests to identify statistically significant genes and to measure the strength of relationships between gene expression and a specific response variable. SAM also uses permutation tests to estimate the FDR after accounting for multiple testing corrections \[[@B14]\]. Genes with FDR *p*-values \< 0.15 and fold-change greater than 1.5 or less than −1.5 were considered significant. Pathway analysis was conducted using MetaCore™ (GeneGo, Inc) software.

Two separate gene expression analyses were performed. The first compared differences in gene expression profiles between the CON and TRAIN subjects before and after the HM training. The second analysis focused only on the TRAIN subjects, by dividing them into high and low responders based on the percent change of their relative VO~2~ max (rVO~2~ max) over the course of the training program. Relative VO~2~ max takes into account and individual's body weight and is defined as milliliters of oxygen per kilogram of bodyweight per minute. The mean percent change in rVO~2~ max was calculated and individuals who fell in the upper quartile (upper 25%) of percent change in rVO~2~ max were labeled as high-responders (10 individuals) and those who fell below the upper quartile were considered low-responders (9 individuals). Gene expression differences between the two groups were studied at baseline and after the 16 weeks of training.

Results
=======

Of the 16 subjects who completed the HM, the average time to completion was 2:22:21 (H:Min:Sec), SD = 26:33. The fastest time was 1:39:00 and the slowest time was 3:11:58. No runner required medical attention after the race. There were no significant differences between the TRAIN and CON groups on any baseline characteristics other than triglycerides, which were significantly higher (p = 0.03) in the TRAIN group (Table [1](#T1){ref-type="table"}).

###### 

Training group and control changes at baseline versus 16 weeks (n=22)

                         **Training group**   **Control group**                                                 
  --------------------- -------------------- ------------------- --------- -------------- -------------- ------ -------
  Weight                    196.76±28.40        192.85±27.60       0.08     188.31±26.11   190.11±26.41   .064   0.316
  Heart rate                76.71±12.41          67.60±11.76       0.002    73.18±12.75    76.05±15.99    .357   0.363
  Systolic BP (mmHg)        121.62±8.45          114.30±9.23      0.0001    116.67±9.86    113.36±7.26    .133   0.088
  Diastolic BP (mmHg)        80.05±9.70          73.15±8.20        0.007     75.67±8.46     77.14±5.20    .542   0.127
  Relative VO~2~ max         37.06±7.12          42.02±8.81       0.00004    38.83±5.03     39.02±6.74    .813   0.35
  Body fat (%)               29.51±8.33          28.18±8.86        0.044     26.84±6.84     27.45±6.87    .116   0.256
  HDL                        46.71±9.61          43.10±6.37        0.055     49.59±7.87     47.05±9.15    .183   0.288
  LDL                       107.05±25.64        103.80±28.03       0.44     100.23±22.39   105.86±20.61   .087   0.358
  Triglycerides             119.90±59.41        116.35±72.01       0.997    85.05±38.84    77.68±40.87    .294   0.03
  CRP                        1.92±2.66            1.64±1.92        0.752     0.84±0.66      1.03±0.83     .269   0.084
  Troponin T                   \<0.01              \<0.01          0.333       \<0.01         \<0.01      .333     1

\*Difference in variable measures between baseline and peak. \*\*Difference at baseline between Training and Control groups.

Comparisons of basic physiological variables were made from baseline to the peak training time-point (17 weeks) in both groups (Table [1](#T1){ref-type="table"}). VO~2~ max increased significantly (p = 0.00004) among those in the TRAIN group during the course of the training program. In addition, the following were significantly decreased: (1) resting heart rate (p = 0.002), (2) percent body fat (p = 0.044), and (3) systolic (p = 0.0001) and diastolic (p = 0.007) blood pressure. Average body weight (p = 0.08) and HDL (p = 0.055) decreased slightly (p = 0.08), but no other measured biomarkers (LDL, Tg, CRP, cTnT) showed significant improvements. There were no significant changes for any variables among the CON subjects (Table [1](#T1){ref-type="table"}). Table [2](#T2){ref-type="table"} shows comparison of echocardiographic changes between TRAIN and CON groups.

###### 

Echocardiographic changes over 16 weeks (n=19)

                                                                 **Training group**   **Control group**                                      
  ------------------------------------------------------------- -------------------- ------------------- ------- ------------- ------------- -------
  Interventricular septum in diastole (cm)                          0.925±0.102          1.003±0.128      0.028   0.925±0.115   0.982±0.138   0.074
  Left ventricular internal diameter in diastole (cm)               4.803±0.490          4.818±0.490      0.864   4.726±0.409   4.876±0.451   0.067
  Left ventricular posterior wall in diastole (cm)                  0.961±0.092          1.075±0.123      0.003   0.930±0.134   0.963±0.133   0.439
  Left ventricular mass (g)                                          186.6±37.4          209.2±30.0       0.009   183.0±31.1    192.1±32.2    0.114
  Left ventricular mass index (g/m^2^)                               91.4±16.8           102.8±12.8       0.008    90.4±15.1     94.2±14.1    0.194
  Left ventricular end-diastolic volume (ml)                         118.4±23.8          144.1±29.6       0.002   124.7±32.7    133.1±30.8    0.186
  Left ventricular end-systolic volume (ml)                          45.8±16.4            52.4±16.7       0.195    43.4±14.0     48.0±14.8    0.11
  Ejection fraction (%)                                               61.9±7.9            63.8±7.8        0.461    65.2±6.5      64.2±6.5     0.47
  Stroke volume (ml)                                                 72.6±14.0            91.6±20.9       0.001    81.2±22.3     85.1±20.4    0.411
  Peak early to late mitral annular velocities (E to A ratio)        1.59±0.37            1.38±0.40       0.03     1.67±0.43     1.70±0.48    0.766

Table [1](#T1){ref-type="table"} shows comparison of echocardiographic changes between TRAIN and CON groups. The following significant changes occurred in the TRAIN group: (1) interventricular septal thickness increased from 0.925±0.102 cm to 1.003±0.128 cm (p=0.028), (2) posterior wall thickness in diastole increased from 0.961±0.092 cm to 1.075±0.123 cm (p=0.003), (3) LV mass increased from 186.6±37.4 g to 209.2±30.0 g (p=0.009), (4) LV mass index increased from 91.4±16.8 g/m^2^ to 102.8±12.8 g/m^2^ (p=0.008), (5) LV end diastolic volume increased from 118.4±23.8 ml to 144.1±29.6 ml (p=0.002), (5) stroke volume increased from 72.6±14.0 ml to 91.6±20. 9ml (p=0.001), and (6) the E to A ratio decreased from 1.59±0.37 to 1.38±0.40 (p=0.03). No significant changes occurred within the control group from baseline to 16 week follow-up.

In comparing the gene expression profiles between TRAIN and CON individuals before training, only 4 genes (*CMKLR1, FOS, IFIT1,* and *PDK4*) showed significant changes (FC \> 1.5, FDR \<0.05) (See Table [3](#T3){ref-type="table"}). All had increased levels of gene expression in the TRAIN group compared to the CON group. No genes were significantly decreased.

###### 

Genes with significantly increased expression levels in active (TRAIN) vs. sedentary (CON) individuals (FDR \<0.05)

   **Before marathon training - Increased gene expression\***             
  ------------------------------------------------------------ ---------- ----------------------
                            7966089                              CMKLR1            1.56
                            7975779                               FOS              1.74
                            7929065                              IFIT1             1.51
                            8141094                               PDK4             1.53
   **After marathon training - increased gene expression\***              
                       **Transcript id**                        **Gene**   **Fold change (FC)**
                            7929256                              \-\--             1.6
                            7928306                              \-\--             1.64
                            7966089                              CMKLR1            1.68
                            7906475                              FCRL6             1.66
                            7996081                              GPR56             1.55
                            7906764                              HSPA6             1.53
                            7964787                               IFNG             1.66
                            8054722                               IL1B             1.71
                            7961175                              KLRC3             1.64
                            7971661                              MIR15A            1.8

\*FDR= false discovery rate (p\<0.05 threshold used).

When comparing profiles from blood collected in TRAIN and CON individuals after the HM training program, ten genes *(CMKLR1, FCRL6, GPR56, HSPA6, IFNG, IL1B, KLRC3, MIR15A)* showed significantly elevated expression (FC \> 1.5, FDR \< .05) (Table [3](#T3){ref-type="table"}) and 53 genes (including *AREG,DEFA3*) were found to be significantly decreased (FC \< −1.5, FDR \< .05) in the TRAIN group (Table [4](#T4){ref-type="table"}). According to pathway analysis, the biological pathways that were significantly up-regulated in the TRAIN individuals after training (p \<0.001) were those involved in inflammatory and immune response, including migration inhibitory factor (MIF) in innate immunity response (p = .00014), bacterial infections in normal airways (p = .0002), apoptosis and survival Nitric Oxide synthesis and signaling (p = .0002) and bacterial infections in CF airways (p = .0002) (data not shown). One biological pathway, translation insulin regulation of translation (p = .00008), showed significantly decreased expression in TRAIN individuals after HM training (data not shown).

###### 

Genes with decreased expression levels in active (TRAIN) vs. sedentary (CON) individuals

   **After marathon training - Decreased gene expression**             
  --------------------------------------------------------- ---------- -------
                           8102787                            \-\--     −1.5
                           8020825                            \-\--     −1.7
                           8037387                            \-\--     −1.65
                           8136471                            \-\--     −1.56
                           8104490                            \-\--     −1.56
                           8084810                            \-\--     −1.54
                           8095744                             AREG     −2.42
                           8095736                             AREG     −2.18
                           8062444                             BPI      −1.74
                           7961075                             CD69     −1.69
                           8149116                            DEFA3     −2.42
                           8149126                            DEFA3     −2.42
                           8149137                            DEFA3     −2.34
                           8084704                            EIF4A2    −1.7
                           8158167                             LCN2     −1.51
                           8086607                             LTF      −1.98
                           7951246                             MMP8     −1.95
                           8012349                             PER1     −1.59
                           7919269                            RNU1-1    −1.55
                           7919349                            RNU1-1    −1.55
                           7973896                            RNU1-1    −1.53
                           7978568                            RNU1-1    −1.53
                           7898375                            RNU1-1    −1.52
                           7898411                            RNU1-1    −1.52
                           7912800                            RNU1-1    −1.52
                           7912850                            RNU1-1    −1.52
                           7919576                            RNU1-1    −1.52
                           7948894                            RNU2-1    −1.53
                           7938295                            RPL27A    −1.51
                           8103975                            SLED1     −1.62
                           7925182                           SNORA14B   −1.5
                           7968234                           SNORA27    −1.52
                           7977075                           SNORA28    −1.56
                           7938293                           SNORA45    −1.6
                           8078918                           SNORA62    −1.86
                           8059708                           SNORA75    −2.03
                           8139456                            SNORA9    −1.55
                           7968232                           SNORD102   −1.67
                           8124940                           SNORD117   −1.67
                           7942592                           SNORD15A   −1.53
                           8059710                           SNORD20    −1.93
                           7903022                           SNORD21    −1.69
                           8159004                           SNORD24    −1.83
                           7948906                           SNORD27    −1.69
                           7948904                           SNORD28    −1.51
                           7948900                           SNORD30    −1.8
                           8030364                           SNORD34    −1.64
                           8159006                           SNORD36B   −1.78
                           8005951                           SNORD42B   −1.63
                           8005957                           SNORD4B    −1.63
                           8023259                           SNORD58A   −1.64
                           7964246                           SNORD59B   −1.56
                           8122265                           TNFAIP3    −1.61

The TRAIN group was categorized into 10 high and 9 low responders based on percent change in their rVO~2~ max. Within the TRAIN group alone, 16 genes showed trending evidence of decreased expression (FC \> −1.5, FDR \< .06) in high vs. low responders, and one gene showed increased gene expression (FC \> 1.5, FDR \< .06) in the high compared to low responders group (Table [5](#T5){ref-type="table"}). Biological processes that were highlighted included those involved in regulation of DNA transcription, translation and other metabolic processes.

###### 

**Genes with significant expression in high responders**^**\***^**(n=10) vs. low responders\*\* (n=9)**

   **After marathon training - Decreased gene expression**                 
  --------------------------------------------------------- -------------- ----------------------
                           7969794                           LOC100132099          −1.58
                           8049530                             LRRFIP1             −1.58
                           7919269                              RNU1-1             −1.89
                           7919349                              RNU1-1             −1.89
                           7898375                              RNU1-1             −1.86
                           7898411                              RNU1-1             −1.86
                           7912800                              RNU1-1             −1.86
                           7912850                              RNU1-1             −1.86
                           7919576                              RNU1-1             −1.86
                           7973896                              RNU1-1             −1.85
                           7978568                              RNU1-1             −1.85
                           7897801                              RNU5E              −1.89
                           7920873                             SNORA42             −3.49
                           8117018                              \-\--              −1.86
                           7932635                              \-\--              −1.63
                           7965150                              \-\--              −1.62
   **After marathon training - increased gene expression**                 
                      **Transcript id**                        **Gene**     **Fold change (FC)**
                           8005225                            LOC162632             2.35

No genes met FDR significance criteria for differential mRNA expression in blood collected at baseline.

\*High Responders are defined as those individuals who fell in the upper quartile (upper 25%) of percent change in rVO~2~ max.

\*\*Low Responders are defined as those individuals who fell below the upper quartile of percent change in rVO~2~ max.

Discussion
==========

This is the first prospective study evaluating the combination of changes in cardiac structure and function, peripheral blood cell gene expression, inflammatory markers, and potential for myocardial injury associated with training for, and performance of, a HM in previously sedentary subjects. The decreases in blood pressure, resting heart rate, and body fat percentage, and the increases in VO~2~ max, observed in our TRAIN group over the course of the program are consistent with previously well-documented responses to exercise training \[[@B15],[@B16]\] and validate the training effect in our HM participants. More interesting is the effect of HM training on biomarkers related to myocardial injury, cardiovascular structural changes by echocardiogram, serum lipids, gene expression and serum inflammatory markers.

In our study, LV mass and wall thickness, and LV end-diastolic and stroke volumes increased significantly after 16 weeks of training. The E to A ratio also decreased throughout training, consistent with a decrease in diastolic relaxation commonly seen in hypertrophied ventricles. These echocardiographic changes have been well-established and recently described to occur in endurance athletes in as little as 90 days \[[@B17]-[@B19]\]. This phenomenon, known as the "athlete's heart," is thought to be due to a long-sustained high cardiac output resulting in a volume-loaded heart that can lead to an increase in LV cavity, LV mass, and wall thickness \[[@B20]-[@B22]\].

Both TRAIN and CON groups had the same inclusion criteria, which enabled us to maximize the comparison after training. When comparing gene expression profiles in blood collected before training in TRAIN versus CON men, 4 genes showed significant changes in gene expression (FC = (1.5-1.7) FDR \< .05) suggesting that the two groups were fairly similar before training. Through pathway analysis, the biological pathways that were significantly up regulated in the TRAIN individuals after training were those primarily involved in the body's inflammatory and immune response. In looking at the specific genes involved of the 53 genes that showed significantly decreased expression in TRAIN individuals after training, Amphiregulin (*AREG*) was most significantly decreased (FC = −2.42). The protein coded by *AREG* is a member of the epidermal growth factor family. *AREG* has both growth factor and inhibitory properties (NCBI, PubMed Gene ID:374). Changes in *AREG* expression in human neutrophils have been related to exercise in previous studies. For example, following 30 minutes of aerobic exercise, *AREG* was shown to increase by 3.4 fold \[[@B23]\]. Although the change is in the opposite direction of the change found in the current study this could be due to the fact that Radom-Aizik et al. \[[@B23]\] examined gene expression changes following acute exercise, whereas our focus is on gene expression changes due to long term, consistent exercise.

Another gene significantly down-regulated in the TRAIN individuals; defensin, alpha 3, neutrophil-specific (*DEFA3*) also has a role in both the immune and inflammatory response (NCBI, PubMed Gene ID: 1668). A previous study linked increased expression of *DEFA3* at both the mRNA and protein level to inflammatory diseases \[[@B24]\]. It is well established that regular exercise helps reduce the amount of total body inflammation and therefore helps prevent the induction of many chronic inflammatory diseases including atherosclerosis. A decrease in total body inflammation is usually associated with a decrease in C-reactive protein, which was not observed in our study. This data suggests that perhaps gene expression changes associated with a decrease in inflammation occur prior to changes in cardiac biomarkers or that subjects with normal CRP at baseline are less likely to show a measurable response to exercise associated with changes in gene expression. Perhaps with longer training, or elevated baseline levels of CPR, similar changes in the cardiac biomarkers would also be seen.

When comparing the TRAIN high responders and low responders, several gene expression differences were noted. Two genes that showed increased expression in high responders before training included *FGFBP2* (FC = 1.76) and *CD160* (FC = 1.55). Both are involved in immune response (NCBI, PubMED Gene ID: 11126).

Of the genes that showed decreased expression in high responders after exercise of particular note is *LRRFIP1* (FC = −1.57). *LRRFIP1* has been identified as having a role as both a regulator of toll-like receptor pathway signaling and transcriptional repression. Its expression has been previously shown to be induced by nicotine and proinflammatory cytokines \[[@B25]\].

Conclusions
===========

In summary, in previously sedentary individuals, intensive training for a HM over 17 weeks leads to increased cardiac and hemodynamic performance that is not associated with longitudinal changes in known cardiac biomarkers. Elevated cTnT occurred in only 1 of 16 subjects who completed the HM. Training is also associated with changes in blood gene expression that reflects the anabolic state of the body, as well as changes in the body's immune and inflammatory response that could be more sensitive precursors to changes in serum biomarkers. Whereas some genes involved in the immune/inflammatory response showed increased expression, others showed decreased expression implying that exercise brings about changes that both suppress aspects of the immune system while stimulating others. Genes with changes in gene expression as response to HM-training include *AREG*, *DEFA3*, *CD160*, *GPR56*, *KLRC3*, and *LRRFIP1*. The results presented here are from a single sample and do not withstand conservative corrections for multiple comparisons. The study's sample is limited to men and therefore cannot necessarily be generalized to the broader population which could include females However, they generate interesting hypotheses about a possible role of genes involved in immunity and inflammation in responding to intensive exercise training, which bear examination in other data sets.
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